Sally Furniss
Well-known member
Efficacious Recombinant Influenza Vaccines Produced by High Yield Bacterial Expression: A Solution to Global Pandemic and Seasonal Needs
Langzhou Song<sup>1</sup><sup>*</sup>, Valerian Nakaar<sup>2</sup>, Uma Kavita<sup>1</sup>, Albert Price<sup>2</sup>, Jim Huleatt<sup>2</sup><sup>?</sup>, Jie Tang<sup>2</sup>, Andrea Jacobs<sup>2</sup>, Ge Liu<sup>1</sup>, Yan Huang<sup>2</sup>, Priyanka Desai<sup>2</sup>, Gail Maksymiuk<sup>2</sup>, Virginia Takahashi<sup>2</sup>, Scott Umlauf<sup>1</sup>, Lucia Reiserova<sup>1</sup>, Rodney Bell<sup>1</sup>, Hong Li<sup>1</sup>, Yi Zhang<sup>1</sup>, William F. McDonald<sup>2</sup>, T. J. Powell<sup>2</sup>, Lynda Tussey<sup>1</sup>
1 VaxInnate Corporation, Cranbury, New Jersey, United States of America2 VaxInnate Corporation, New Haven, Connecticut, United States of America
Abstract
It is known that physical linkage of TLR ligands and vaccine antigens significantly enhances the immunopotency of the linked antigens. We have used this approach to generate novel influenza vaccines that fuse the globular head domain of the protective hemagglutinin (HA) antigen with the potent TLR5 ligand, flagellin. These fusion proteins are efficiently expressed in standard E. coli fermentation systems and the HA moiety can be faithfully refolded to take on the native conformation of the globular head. In mouse models of influenza infection, the vaccines elicit robust antibody responses that mitigate disease and protect mice from lethal challenge. These immunologically potent vaccines can be efficiently manufactured to support pandemic response, pre-pandemic and seasonal vaccines.
Citation: Song L, Nakaar V, Kavita U, Price A, Huleatt J, et al. (2008) Efficacious Recombinant Influenza Vaccines Produced by High Yield Bacterial Expression: A Solution to Global Pandemic and Seasonal Needs. PLoS ONE 3(5): e2257. doi:10.1371/journal.pone.0002257
Editor: Douglas F. Nixon, University of California San Francisco, United States of America
Received: April 2, 2008; Accepted: April 7, 2008; Published: May 21, 2008
Copyright: ? 2008 Song et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work is supported by the VaxInnate Corporation.
Competing interests: All the authors are employees of the VaxInnate Corporation.
* E-mail: langzhou.song@vaxinnate.com
? Current address: Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America
http://www.plosone.org/article/info:doi/10.1371/journal.pone.0002257
Langzhou Song<sup>1</sup><sup>*</sup>, Valerian Nakaar<sup>2</sup>, Uma Kavita<sup>1</sup>, Albert Price<sup>2</sup>, Jim Huleatt<sup>2</sup><sup>?</sup>, Jie Tang<sup>2</sup>, Andrea Jacobs<sup>2</sup>, Ge Liu<sup>1</sup>, Yan Huang<sup>2</sup>, Priyanka Desai<sup>2</sup>, Gail Maksymiuk<sup>2</sup>, Virginia Takahashi<sup>2</sup>, Scott Umlauf<sup>1</sup>, Lucia Reiserova<sup>1</sup>, Rodney Bell<sup>1</sup>, Hong Li<sup>1</sup>, Yi Zhang<sup>1</sup>, William F. McDonald<sup>2</sup>, T. J. Powell<sup>2</sup>, Lynda Tussey<sup>1</sup>
1 VaxInnate Corporation, Cranbury, New Jersey, United States of America2 VaxInnate Corporation, New Haven, Connecticut, United States of America
Abstract
It is known that physical linkage of TLR ligands and vaccine antigens significantly enhances the immunopotency of the linked antigens. We have used this approach to generate novel influenza vaccines that fuse the globular head domain of the protective hemagglutinin (HA) antigen with the potent TLR5 ligand, flagellin. These fusion proteins are efficiently expressed in standard E. coli fermentation systems and the HA moiety can be faithfully refolded to take on the native conformation of the globular head. In mouse models of influenza infection, the vaccines elicit robust antibody responses that mitigate disease and protect mice from lethal challenge. These immunologically potent vaccines can be efficiently manufactured to support pandemic response, pre-pandemic and seasonal vaccines.
Citation: Song L, Nakaar V, Kavita U, Price A, Huleatt J, et al. (2008) Efficacious Recombinant Influenza Vaccines Produced by High Yield Bacterial Expression: A Solution to Global Pandemic and Seasonal Needs. PLoS ONE 3(5): e2257. doi:10.1371/journal.pone.0002257
Editor: Douglas F. Nixon, University of California San Francisco, United States of America
Received: April 2, 2008; Accepted: April 7, 2008; Published: May 21, 2008
Copyright: ? 2008 Song et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work is supported by the VaxInnate Corporation.
Competing interests: All the authors are employees of the VaxInnate Corporation.
* E-mail: langzhou.song@vaxinnate.com
? Current address: Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America
http://www.plosone.org/article/info:doi/10.1371/journal.pone.0002257